Active Ingredient History
Mesalamine, also known as Mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism. Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is used for the treatment of active ulcerative proctitis. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Colitis, Ulcerative (approved 1993)
Acquired Immunodeficiency Syndrome (Phase 4)
Adenoma (Phase 2)
Beryllium (Phase 1/Phase 2)
Breast Neoplasms (Phase 2)
Cocaine-Related Disorders (Phase 2)
Colitis (Phase 2)
Colitis, Collagenous (Phase 3)
Colitis, Lymphocytic (Phase 3)
Colitis, Microscopic (Phase 2/Phase 3)
Colitis, Ulcerative (Phase 4)
Colonic Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 2)
Crohn Disease (Phase 4)
Cytokines (Phase 2)
Diabetes Mellitus, Type 2 (Phase 1)
Dialysis (Phase 1)
Diarrhea (Phase 2/Phase 3)
Digestive System Diseases (Phase 2/Phase 3)
Diverticular Diseases (Phase 3)
Diverticulitis (Phase 3)
Diverticulosis, Colonic (Phase 2)
Drug Evaluation (Phase 2)
Eosinophilic Esophagitis (Phase 2)
Fissure in Ano (Phase 1/Phase 2)
Gastrointestinal Diseases (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Hermanski-Pudlak Syndrome (Phase 2)
HIV Infections (Phase 4)
Immune System Diseases (Phase 4)
Inflammation (Phase 1/Phase 2)
Inflammatory Bowel Diseases (Phase 2/Phase 3)
Intestinal Diseases (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 4)
Irritable Bowel Syndrome (Phase 4)
Kidney Failure, Chronic (Phase 1)
Lentivirus Infections (Phase 4)
Lymphocytes (Phase 2)
Malnutrition (Phase 1/Phase 2)
Melanoma (Phase 2)
Metabolism (Phase 2)
Obesity (Phase 1)
Oral Ulcer (Phase 3)
Polycystic Ovary Syndrome (Phase 2)
Proctitis (Phase 3)
Quality of Life (Phase 4)
Rectal Neoplasms (Phase 2)
Recurrence (Phase 3)
Renal Dialysis (Phase 1)
Schizophrenia (Phase 3)
Sexually Transmitted Diseases (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
